跳至主要内容
临床试验/CTRI/2025/12/098783
CTRI/2025/12/098783尚未招募2/3 期

A Parallel Comparative Study To Evaluate The Efficacy Of Rudraksha Churna In Comparison To Jatamansyadi Kwath Churna In The Management of Stage-1 Hypertension

Institute for Ayurved studies and research1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年5月15日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
To evaluate the efficacy of Rudraksha Churna and Jatamansyadi

研究概览

简要总结

Raktagata vata can be understood by assessing the involved Doshas, Dooshyas, Srotases, Samuthan.

Sharira doshas (Vata - Pitta - Kapha) and Mansika doshas (Raja - Tama) gets vitiated by nidana sewans

which leads to Agni Mandhya, Dhatu Dushti (Rasa-Rakta) and Srotodushti (Rasavaha-Raktavaha). As a

result of this Vyana Prakopa takes place and Sthanasamsraya occurs in Dhamni, Shira and Sarwang

Sharira due to the Vikshepa bala of Vyana Vayu which leads to rise in the blood pressure. In Raktagata

vata, Rakta dhatu gets vitiated by Vata dosha, leading and it is unable to perform its normal function and

symptoms like Tivraruja, Santapa, Vaivarnya, Aruchi, Krishata Bhrama, Klama, Shirashula can be

observed in the patient. According to Acharya Charaka to understand a new clinical entity, which is not

described in the Samhita and physician is unable to diagnose the disease, then the treatment protocol

should be designed by assessing its Prakruti, Samuthan and Adhishtana

.

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and many of these deaths can

be prevented by treating hypertension. Blood pressure is created by the force of blood pushing against the

walls of blood vessels (arteries) as it is pumped by the heart. The higher the pressure, the harder the heart

must pump and the more damage this excess pressure causes to many parts of the body, especially the

brain, heart and kidneys. In about 85% -95% of cases, a specific underlying cause of hypertension cannot

be identified and such hypertension is termed as essential hypertension. To catalyze national action, the

World Health Assembly adopted a comprehensive Global Monitoring Framework in 2013, comprised of nine voluntary global targets to be reached by 2025 which included a 25% relative reduction in the

prevalence of raised blood pressure.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patient willing for clinical trial and ready to give written Consent.
  • Patients between the age group of
  • 60 years of either gender.
  • Pre-diagnosed or freshly diagnosed patient of Stage-1 Hypertension.
  • SBP 140-159mmhg, DBP 90-99mmhg (HTN stage 1).

排除标准

  • Patient having an Age below 30 and above 60 years.
  • SBP greater than 160 mmhg, DBP greater than 100 mmhg (HTN stage 2).
  • Cases linked renal, endocrine, cardiovascular diseases (Secondary Hypertension).
  • Other systemic diseases such as Diabetes, CKD etc.
  • Pregnancy and Lactation.

结局指标

主要结局

To evaluate the efficacy of Rudraksha Churna and Jatamansyadi

时间窗: 28 Days

Kwath Churna in reducing systolic and diastolic blood pressure.

时间窗: 28 Days

次要结局

  • Improvement in World Health Organization Quality of life (WHOQOL Bref) Scale Score,(Improvement in Hamilton Anxiety Rating Scale Score (HAM-A).)

研究者

发起方
Institute for Ayurved studies and research
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Divya

Institute for Ayurved Studies and Reasearch kurukshetra

研究点 (1)

Loading locations...

相似试验

RUDRAKSHA CHURNA vs JATAMANSYADI KWATH CHURNA IN... | 临床试验